Wijnand H P, Timmer C J
Comput Programs Biomed. 1983 Aug-Oct;17(1-2):73-88. doi: 10.1016/0010-468x(83)90027-2.
For bioequivalence testing of pharmaceutical formulations of the same drug entity, it is not sufficient to carry out an analysis of variance on the characteristic to be evaluated (e.g., area under the plasma level vs time curve, half-life of elimination, time to plasma-peak level, plasma peak level) and to establish 'classical' 95% confidence intervals for the difference or the ratio of the characteristic concerned. In the past 10 years, several approaches have been proposed as an aid in decision-making: Westlake's 95% intervals, Rodda and Davis' probabilities, Fluehler's posterior probability histograms and the evaluation of the residual variation coefficient. A survey of these approaches is given, together with a discussion of their merits, their differences and their similarities. It is recommended that the final evaluation should be supported by probability density plots, which facilitate easy understanding of the differences and similarities between the various approaches. A bioequivalence study with two types of oral tablets containing bepridil, a new anti-anginal drug, is used as an example. Computer programs are presented, which enable the user to easily apply the various approaches in order to meet requirements of regulatory agencies.
对于同一药物实体的药物制剂进行生物等效性测试时,仅对待评估特征(例如血药浓度-时间曲线下面积、消除半衰期、血药峰浓度时间、血药峰浓度)进行方差分析并为相关特征的差异或比值建立“经典”的95%置信区间是不够的。在过去十年中,已经提出了几种辅助决策的方法:韦斯特莱克95%区间、罗达和戴维斯概率、弗勒勒后验概率直方图以及残余变异系数评估。本文对这些方法进行了综述,并讨论了它们的优点、差异和相似之处。建议最终评估应以概率密度图为辅助,这有助于轻松理解各种方法之间的差异和相似之处。以一项使用两种含新型抗心绞痛药物苄普地尔的口服片剂的生物等效性研究为例。文中给出了计算机程序,用户可通过这些程序轻松应用各种方法,以满足监管机构的要求。